Showing results (141-150 of 157) with videos related to
Sort By:
Pageof 16
Journal of Medical Genetics|July 5, 2005
The location of constitutional neurofibromatosis 2 (NF2) splice site mutations is associated with the severity of NF2M E Baser, L Kuramoto, R Woods, et al.Neurology|December 30, 2004
Correlations between molecular profile and radiologic pattern in oligodendroglial tumorsF Laigle-Donadey, N Martin-Duverneuil, J Lejeune, et al.Neurology|July 28, 2004
Initial chemotherapy in gliomatosis cerebriM Sanson, S Cartalat-Carel, S Taillibert, et al.Neurology|April 30, 2010
All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2M Labussière, A Idbaih, X-W Wang, et al.Journal of Neurosurgery|June 1, 1996
Stereotactic radiosurgery for trigeminal neuralgia: a multiinstitutional study using the gamma unitD Kondziolka, L D Lunsford, J C Flickinger, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 31, 2004
Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletionsK Hoang-Xuan, L Capelle, M Kujas, et al.British Journal of Cancer|October 15, 2014
TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlationsM Labussière, A L Di Stefano, V Gleize, et al.Neurology|May 6, 2009
Bevacizumab and irinotecan for recurrent oligodendroglial tumorsS Taillibert, L A Vincent, B Granger, et al.Archives De Pediatrie : Organe Officiel De La Societe Francaise De Pediatrie|February 28, 2002
[Neurofibromatosis 1: recommendations for management]S Pinson, A Créange, S Barbarot, et al.Neurology|May 23, 2007
Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcomeG Kaloshi, A Benouaich-Amiel, F Diakite, et al.Pageof 16